Department of Oral and Maxillofacial Surgery, School of Life Dentistry at Tokyo, The Nippon Dental University, Chiyoda-ku, Tokyo, Japan.
Tissue Eng Part A. 2022 Sep;28(17-18):749-759. doi: 10.1089/ten.TEA.2021.0225. Epub 2022 Jun 21.
Platelet-rich fibrin (PRF) prepared from venous blood is used in the clinic to improve soft tissue wound healing. Nevertheless, arterial blood or bone marrow aspirate might also be a candidate for the source of PRF-like concentrates. The purpose of the present study was to investigate blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate to determine its respective regenerative potential . Arterial blood-derived PRF (Ar-PRF), venous blood-derived PRF (Ve-PRF), and solid-type bone marrow aspirate concentrate (sBMAC) were prepared from New Zealand white rabbits. Each clot was evaluated for its cytocompatibility and regenerative potential on primary rabbit gingival fibroblasts and osteoblasts. Both gingival fibroblasts and osteoblasts treated with each concentrate showed excellent viability. Interestingly, the sBMAC-treated cells demonstrated a significantly greater migratory potential than the other treatment groups. Furthermore, higher mRNA levels of , , and in gingival fibroblasts were observed in the sBMAC group compared with the Ar-PRF and Ve-PRF groups. Greater osteoblast differentiation potential, including higher expression and mineralization potential, was found in osteoblasts treated with sBMAC. However, minor differences between the behaviors of cells treated with Ar-PRF and Ve-PRF were observed. In conclusion, sBMAC might be a new candidate for promoting wound healing and bone regeneration. Further preclinical and clinical experiments are necessary to prove the regenerative potential of sBMAC in the body. Impact Statement Blood concentrate material such as platelet-rich plasma or platelet-rich fibrin (PRF) is used in clinical practice to promote tissue regeneration in the field of dentistry, orthopedic surgery, and plastic surgery. The present study introduces a new type of solid bone marrow aspirate concentrate material and, for the first time, shows its excellent regenerative potential in both gingival fibroblasts and osteoblasts compared with that of conventional PRF.
富血小板纤维蛋白（PRF）来源于静脉血，目前已在临床上用于促进软组织伤口愈合。然而，动脉血或骨髓抽吸物也可能成为 PRF 样浓缩物的来源。本研究旨在从动脉血、静脉血和骨髓抽吸物中获取血液/骨髓抽吸浓缩物，以确定其各自的再生潜力。从新西兰白兔中提取动脉血来源的富血小板纤维蛋白（Ar-PRF）、静脉血来源的富血小板纤维蛋白（Ve-PRF）和固态骨髓抽吸浓缩物（sBMAC）。对每种凝块的细胞相容性和对原代兔牙龈成纤维细胞和成骨细胞的再生潜力进行评估。用每种浓缩物处理的牙龈成纤维细胞和成骨细胞均表现出良好的活力。有趣的是，sBMAC 处理的细胞表现出比其他处理组更强的迁移潜力。此外，与 Ar-PRF 和 Ve-PRF 组相比，sBMAC 组牙龈成纤维细胞中 、 和 的 mRNA 水平更高。用 sBMAC 处理的成骨细胞表现出更高的成骨细胞分化潜力，包括更高的 表达和矿化潜力。然而，用 Ar-PRF 和 Ve-PRF 处理的细胞行为之间观察到较小的差异。总之，sBMAC 可能是促进伤口愈合和骨再生的新候选物。需要进一步的临床前和临床试验来证明 sBMAC 在体内的再生潜力。
